Knockin mice are genetically engineered models with precise modifications such as the insertion of human genes or point mutations into their genome. These models are vital for studying human gene function, disease mechanisms, and testing therapeutic interventions in a controlled, predictable manner.

Generating knock-in (KI) mice involves inserting a specific DNA sequence into a targeted genomic locus. The process generally follows these 4 steps:

Design & Vector Construction: Create a donor DNA template containing your gene of interest flanked by homology arms (sequences matching the target site).

Gene Editing Technology:

CRISPR/Cas9: The most common method. gRNA directs Cas9 to cut the DNA, allowing the donor sequence to be inserted during repair.

ES Cell Targeting: Traditional method involving homologous recombination in embryonic stem cells for complex or large insertions.

Embryo Manipulation: Microinject the editing components into zygotes (for CRISPR) or inject targeted ES cells into blastocysts, then implant them into surrogate mothers.

Screening & Breeding: Genotype the offspring via PCR/Sequencing to confirm integration and breed them to ensure germline transmission.

At its simplest, knockout (KO) is about "loss of function," while knockin (KI) is about "gain or alteration of function." Both leverage precise genome editing but serve different research purposes:

Knockout (KO): Involves the inactivation or deletion of a specific gene. It is used to study the biological necessity of a gene by observing what happens when its function is completely removed.

Knockin (KI): Involves the insertion of a specific exogenous DNA sequence (such as a humanized gene, a reporter like GFP, or a point mutation) into a targeted locus. It is used to model human diseases or track gene expression.

Knock-in (KI) mice are indispensable in biomedical research because they can mimic specific genetic alterations found in human patients. Unlike knockout mice, which primarily study "loss-of-function," knock-in models allow for the study of "gain-of-function" or "change-of-function" mutations.

Key disease areas studied using KI models include:

Rare Genetic Disorders: Modeling specific human point mutations (e.g., Single Nucleotide Polymorphisms) to study conditions like Cystic Fibrosis or Duchenne Muscular Dystrophy (DMD).

Neurodegenerative Diseases: Inserting human genes associated with Alzheimer’s, Parkinson’s, or Huntington’s disease (e.g., humanized MAPT or APP genes) to study protein aggregation and neuronal decay.

Cancer & Oncology: Studying the effects of specific oncogenic mutations (e.g., KRAS or p53 point mutations) or creating reporter strains to track tumor growth and metastasis in vivo.

Cardiovascular Diseases: Modeling hereditary cardiomyopathies by introducing specific contractile protein mutations.

The generation of knock-in (KI) mice relies on the precise insertion of exogenous DNA into a specific genomic locus. To ensure genetic stability and germline transmission, researchers primarily utilize the following advanced gene-targeting strategies:

1. Traditional ES Cell-Based Gene Targeting
This remains the "gold standard" for complex large-fragment insertions.

Mechanism: A targeting vector is introduced into Embryonic Stem (ES) cells via electroporation. Through the natural process of homologous recombination, the DNA sequence in the vector replaces the corresponding sequence in the cell's genome.

Process: Successfully targeted ES cells are selected and injected into blastocysts, which are then transferred to surrogate mothers to produce chimeric mice.

Best For: Projects requiring high genomic integrity, large-scale humanization, or conditional gene modifications (e.g., Cre-LoxP systems).

2. Cyagen’s Proprietary TurboKnockout® Technology
To overcome the long timelines associated with traditional ES cell methods, Cyagen developed the TurboKnockout® platform.

The Cyagen Advantage: This technology optimizes the standard ES cell-based approach by utilizing a unique cell-mediated logic that can bypass the chimera stage. It allows for the generation of heterozygous F1 mice directly.

Benefits: It reduces the project timeline to as little as 6–8 months while maintaining the extreme precision and stability of ES cell targeting.

Best For: Complex preclinical models that require both speed and absolute accuracy in genomic positioning.